Fast injection creates a sudden bolus of fluid in the subcutaneous tissue, which causes pressure, stinging, and sometimes lump formation
However, 503A pharmacies compounding patient-specific preparations on a prescription-by-prescription basis occupy a different regulatory category and may continue in Michigan depending on evolving FDA enforcement guidance
A meta-analysis of eight clinical trials including ELIXA (lixisenatide), LEADER (liraglutide), SUSTAIN-6 (subcutaneous injectable semaglutide), EXSCEL (exenatide), Harmony Outcomes (albiglutide), REWIND (duraglutide), PIONEER-6 (oral administrated semaglutide) and AMPLITUDE-O (efpeglenatide) showed that GLP-1RA reduced MACE by 14% (HR 0.86, 95% CI 0.800.93) [11]
Both medication classes can influence cardiovascular parameters and glucose metabolism in ways that may require monitoring and dose adjustments